Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

  • Rodríguez-Agudo, Rubén
  • González-Recio, Irene
  • Serrano-Maciá, Marina
  • Bravo, Miren
  • Petrov, Petar D.
  • Blaya, Delia
  • Herranz, José María
  • Mercado-Gómez, María
  • Rejano-Gordillo, Claudia María
  • Lachiondo-Ortega, Sofía
  • Gil-Pitarch, Clàudia
  • Azkargorta, Mikel
  • Liempd, Sebastiaan Martijn van
  • Martínez-Cruz, Luis Alfonso
  • Simão, A. L.
  • Elortza, Félix
  • Martín, César
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Delgado, Teresa C.
  • Argemi, Josepmaria
  • Bataller, Ramón
  • Schoonjans, Kristina
  • Banales, Jesús M.
  • Castro, Rui E.
  • Sancho-Bru, Pau
  • Ávila, Matías A.
  • Julve, Josep
  • Jover, Ramiro
  • Mabe, Jon
  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Martínez-Chantar, María Luz
© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background & Aims] Current therapies for the treatment of alcohol-related liver disease (ALD) have proven largely ineffective. Patients relapse and the disease progresses even after liver transplantation. Altered epigenetic mechanisms are characteristic of alcohol metabolism given excessive acetate and NAD depletion and play an important role in liver injury. In this regard, novel therapeutic approaches based on epigenetic modulators are increasingly proposed. MicroRNAs, epigenetic modulators acting at the post-transcriptional level, appear to be promising new targets for the treatment of ALD., [Methods] MiR-873-5p levels were measured in 23 liver tissue from Patients with ALD, and GNMT levels during ALD were confirmed using expression databases (transcriptome n = 62, proteome n = 68). High-resolution proteomics and metabolomics in mice following the Gao-binge model were used to investigate miR-873-5p expression in ALD. Hepatocytes exposed to 50 mM alcohol for 12 h were used to study toxicity. The effect of anti-miR-873-5p in the treatment outcomes of ALD was investigated., [Results] The analysis of human and preclinical ALD samples revealed increased expression of miR-873-5p in the liver. Interestingly, there was an inverse correlation with NNMT, suggesting a novel mechanism for NAD depletion and aberrant acetylation during ALD progression. High-resolution proteomics and metabolomics identified miR-873-5p as a key regulator of NAD metabolism and SIRT1 deacetylase activity. Anti-miR-873-5p reduced NNMT activity, fuelled the NAD salvage pathway, restored the acetylome, and modulated the levels of NF-κB and FXR, two known SIRT1 substrates, thereby protecting the liver from apoptotic and inflammatory processes, and improving bile acid homeostasis., [Conclusions] These data indicate that targeting miR-873-5p, a repressor of GNMT previously associated with NAFLD and acetaminophen-induced liver failure. is a novel and attractive approach to treating alcohol-induced hepatoxicity., [Impact and implications] The role of miR-873-5p has not been explicitly examined in the progression of ALD, a pathology with no therapeutic options. In this study, inhibiting miR-873-5p exerted hepatoprotective effects against ALD through rescued SIRT1 activity and consequently restored bile acid homeostasis and attenuated the inflammatory response. Targeting hepatic miR-873-5p may represent a novel therapeutic approach for the treatment of ALD., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001136-S)., This work was supported by grants from Ministerio de Ciência, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER (to MLM-C); Ministerio de Ciência e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (to MLM-C); Instituto de Salud Carlos III, Proyectos Investigación en Salud DTS20/00138 (to MLM-C); La Caixa Scientific Foundation (HR17-00601) (for REC, MLM-C and JMB); La Caixa Consortium (to JMB, REC, KS and MLM-C); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by the European Union, PI20/00690, PI20/00765, PI20/01663 and PI21/00922 (to RJ, PS-B, JA and JMB respectively); Miguel Servet Programme CPII19/00008 (to JMB); AMMF-The Cholangiocarcinoma Charity (EU/2019/AMMFt/001) (to JMB); PSC Partners US and PSC Supports UK 06119JB (to JMB); European Union’s Horizon 2020 Research and Innovation Program, 825510 (for JMB) Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (Madrid, Spain) grant PI21/00770 (for JJ), Fundação para a Ciência e a Tecnologia (grants PTDC/MED-PAT/31882/2017 and EXPL/MED-OUT/1317/2021 to REC and ALS)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bariatric Surgery Is Associated with Alcohol-Related Liver Disease and Psychiatric Disorders Associated with AUD

  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Marti-Aguado, David
  • Kennedy, Kevin
  • Fernández-Carrillo, Carlos
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Morales-Arraez, Dalia
  • Atkinson, Stephen R.
  • Clemente-Sanchez, Ana
  • Argemi, Josepmaria
  • Bataller, Ramon|||0000-0002-1119-7799
Bariatric surgery can increase the risk of addictive disorders and nutritional deficiencies. The aim of this study was to evaluate the association between bariatric surgery and alcohol use disorder (AUD), alcohol-related liver disease (ALD), and psychiatric disorders associated with AUD. The impact of vitamin D deficiency in these associations was also investigated. A cross-sectional study was performed using the National Inpatient Sample database and its ICD-9 codes information. Diagnostic and comorbidity data from hospital discharges were obtained from patients with bariatric surgery and other abdominal surgeries between 2005 and 2015. The two groups were then compared for alcohol-related outcomes after propensity-score matching. The final study cohort included 537,757 patients with bariatric surgery and 537,757 with other abdominal surgeries. The bariatric surgery group had an increased risk of AUD [odds ratio (OR): 1.90; 95% CI: 1.85-1.95], ALD [OR: 1.29; 95% CI: 1.22-1.37], cirrhosis [OR, 1.39; 95% CI: 1.37-1.42], and psychiatric disorders associated with AUD [OR, 3.59; 95% CI: 3.37-3.84]. Vitamin D deficiency did not impact in the association between bariatric surgery and AUD, ALD, or psychiatric disorders associated with AUD. Bariatric surgery is associated with an increased prevalence of AUD, ALD, and psychiatric disorders associated with AUD. These associations appear to be independent from vitamin D deficiency. The online version contains supplementary material available at 10.1007/s11695-023-06490-w.